Role of enteroendocrine L-cells in arginine vasopressin-mediated inhibition of colonic anion secretion

Ramona Pais¹, Juraj Rievaj¹, Claire Meek¹, Gayan De Costa², Samanthie Jayamaha², R. Todd Alexander³, Frank Reimann¹ and Fiona Gribble¹

¹The Wellcome Trust – MRC Institute of Metabolic Science, Metabolic Research Laboratories, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
²Department of Clinical Biochemistry, Cambridge University Hospitals, Addenbrooke’s Hospital, Cambridge, UK
³Departments of Paediatrics & Physiology, Faculty of Medicine & Dentistry, University of Alberta, Edmonton, Alberta, Canada

Key points
- Arginine vasopressin (AVP) stimulates the release of enteroendocrine L-cell derived hormones glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) in vitro from mouse and human colons.
- This is mediated by the AVP receptor 1B, which is highly enriched in colonic L-cells and linked to the elevation of L-cell calcium and cAMP concentrations.
- By means of Ussing chambers, we show that AVP reduced colonic anion secretion, although this was blocked by a specific neuropeptide Y receptor Y1 receptor antagonist, suggesting that L-cell-released PYY acts locally on the epithelium to modulate fluid balance.
- In human serum samples, PYY concentrations were higher in samples with raised osmolality and copeptin (surrogate marker for AVP).
- These findings describe, for the first time, the role of L-cells in AVP regulated intestinal fluid secretion, potentially linking together hormonal control of blood volume and blood glucose levels, and thus adding to our understanding of the complex pathways involved in the gut hormonal response to different stimuli.

Abstract Arginine vasopressin (AVP) regulates fluid balance and blood pressure via AVP receptor (AVPR2) in the kidney and AVP receptor 1A in vascular smooth muscle. Its role in intestinal function has received less attention. We hypothesized that enteroendocrine L-cells producing glucagon-like peptide 1 (GLP-1) and peptide YY (PYY) may be a target of AVP and contribute to the control of fluid balance. Avpr1b expression was assessed by quantitative RT-PCR on fluorescence-activated cell sorting-isolated L- and control cells and was enriched in colonic L-cells. AVP stimulated GLP-1 and PYY release from primary cultured murine and human colonic cells and was associated with elevated calcium and cAMP concentrations in L-cells as measured in cultures from GLU-Cre/ROSA26-GCaMP3 and GLU-Epac2camps mice. An antagonist of AVPR1B reduced AVP-triggered hormone secretion from murine and human cells. In Ussing chambers, basolaterally applied AVP reduced colonic anion secretion and this effect was blocked by a specific neuropeptide Y receptor Y1 (NPY1R) antagonist. In human serum, PYY concentrations were higher in samples with raised osmolality or copeptin (a surrogate marker for AVP). In conclusion, we propose that AVP activates L-cell AVPR1B, causing GLP-1 and PYY secretion. PYY in turn reduces colonic anion secretion via epithelial NPY1R. Our data suggest L-cells are active players in the hypothalamic control of intestinal fluid homeostasis, providing a potential link between the regulation of blood volume/pressure/osmolality and blood glucose.
Introduction

The regulation of fluid balance is vital for human health and is under the control of a number of hormones, including arginine vasopressin (AVP; anti-diuretic hormone). AVP is produced in the supraoptic and paraventricular nuclei in the hypothalamus and travels along the neuronal axons to the posterior pituitary gland where it is released into the bloodstream. Hypotension and hyperosmolality stimulate AVP release, such as might occur during dehydration or fluid loss. AVP can bind to three subtypes of G-protein coupled AVP receptor (AVPR), namely AVPR1A, AVPR1B and AVPR2, which are differently expressed in various tissues, exerting a variety of actions (Koshimizu et al. 2012). AVP acts upon the kidney via AVPR2 to increase the water permeability of the collecting ducts, thereby promoting water reabsorption and facilitating the production of concentrated urine. AVP acts upon smooth muscle via AVPR1A to increase peripheral vascular resistance and raise blood pressure during hypovolaemic shock. Vasopressin-induced platelet aggregation also appears to be mediated via AVPR1A (Launay et al. 1987). The role of the AVPR1B is less clear, although it appears to be present in the pituitary and adrenal medulla and promotes the release of adrenocorticotropic hormone and catecholamines, respectively.

Another potential site of action for AVP might be the gastrointestinal tract, which is the main route of water entry into the body and an important site of fluid loss in pathological states characterized by vomiting or diarrhoea. Intestinal water balance is known to be hormonally regulated. Both glucocorticoids and mineralocorticoids stimulate intestinal sodium and water absorption, with mineralocorticoids predominantly affecting the distal part of the colon, whereas glucocorticoids act along the length of both the small and large bowel (Levitan & Ingelfinger, 1965; Charney et al. 1975; Binder et al. 1989; Turnamian & Binder, 1989). Human and rodent intestine both express vasopressin receptors (Monstein et al. 2008; Ferrier et al. 2010). The effect of AVP on intestinal water and salt balance has been investigated previously. *In vitro*, AVP increased colonic sodium, chloride and water absorption at the same time as decreasing anion secretion (Grady et al. 1970; Bridges et al. 1983; Bridges et al. 1984; Knobloch et al. 1989; Vicentini-Paulino, 1992). The role of AVP in altering intestinal water balance was also supported by its ability to increase the pericryptal sodium concentration and upregulate aquaporin-2 expression in the rat distal colon (Cristià et al. 2007). However, the exact mechanism of intestinal AVP action has never been examined. Furthermore, a few *in vivo* studies failed to confirm that AVP stimulates intestinal salt and water absorption as observed *in vitro*, possibly as a result of the effects of AVP on gastrointestinal vasculature and/or motility (Levitan & Mauer, 1968; Dennhardt et al. 1979).

Besides being a hormonal target, the intestine also produces multiple hormones such as gastrin, ghrelin, cholecystokinin, glucagon-like peptide 1 (GLP-1) and peptide YY (PYY). These hormones are secreted from mucosal enteroendocrine cells and co-ordinate nutrient absorption and disposal, hunger and satiety (Gribble & Reimann, 2015). GLP-1 and PYY are secreted by L-cells, which are found in high numbers in the distal ileum and colon. They appear to be released under similar conditions; for example, when nutrients in the gastrointestinal lumen make contact with L-cells after a meal (Pais et al. 2016a). Although the main role for GLP-1 appears to be the regulation of glucose homeostasis, the clinical use of GLP-1 receptor agonists for the treatment of type 2 diabetes has revealed their effects on heart rate and blood pressure, probably reflecting the expression of GLP1R in the heart, brainstem, kidney and arterial vasculature (Pyke et al. 2014; Richards et al. 2014). PYY, besides its effects on appetite and gastrointestinal motility, is also a strong inhibitor of intestinal water and anion secretion (Cox, 2007a,b). In humans, PYY reduces intestinal secretion (Playford et al. 1990) via actions on the neuropeptide Y receptors Y1 and Y2 (NPY1R and NPY2R) (Cox, 2008). Thus, L-cells have the potential to influence both glucose homeostasis and intestinal water balance. The present study aimed to investigate whether hormone secretion from L-cells was affected by AVP release in *vivo* and *in vitro* and the systemic consequences.

Methods

Solutions and compounds

All compounds were purchased from Sigma-Aldrich (Poole, UK) unless otherwise stated. BIBP3226...
tripfluoroacetate was purchased from Bioquote (York, UK). 
SSR-149415 (SSR) was purchased from Axon Medchem 
BV (Groningen, The Netherlands). The composition of 
standard bath solution used in the secretion and imaging 
experiments was: 4.5 mmol l$^{-1}$ KCl, 138 mmol l$^{-1}$ 
NaCl, 4.2 mmol l$^{-1}$ NaHCO$_3$, 1.2 mmol l$^{-1}$ NaH$_2$PO$_4$, 
2.6 mmol l$^{-1}$ CaCl$_2$, 1.2 mmol l$^{-1}$ MgCl$_2$ and 10 mmol l$^{-1}$ 
Hepes (adjusted to pH 7.4 with NaOH). For experiments 
where CoCl$_2$ was used, carbonates and phosphates were 
omitted from the saline buffer and the osmolality was 
compensated with additional NaCl (143 mmol l$^{-1}$ total).

The composition of Ringer solution used in the 
Ussing chamber experiments was: 120 mmol l$^{-1}$ NaCl, 
3 mmol l$^{-1}$ KCl, 0.5 mmol l$^{-1}$ MgCl$_2$, 1.25 mmol l$^{-1}$ 
CaCl$_2$, 23 mmol l$^{-1}$ NaHCO$_3$ and 10 mmol l$^{-1}$ glucose.

**Ethical approval**

All animal procedures were approved by the University 
of Cambridge Animal Welfare and Ethical Review Body 
and conformed to the Animals (Scientific Procedures) 
Act 1986 Amendment Regulations (SI 2012/3039). The 
work was performed under the UK Home Office Project 
License 70/7824. The ethical principles under which 
The journal of Physiology operates were fully understood 
and the work complies with the animal ethics checklist. 
The experiments presented did not involve regulated 
procedures, other than the breeding of transgenic mice, 
or in vivo intervention studies. Male and female mice, 
aged 3–6 months on a C57BL6 background, were housed 
in individually-ventilated cages with access to water and 
chow available ad libitum. Mice were killed by cervical 
dislocation and the intestinal tissue was used in the 
experiments.

**Transgenic mice**

GLU-Venus mice have been described previously 
(Reimann et al. 2008). GLU-Cre mice were created using 
a bacterial artificial construct, as described previously 
(Parker et al. 2012), and express Cre recombinase under 
the control of the proglucagon promoter. Labelling of 
intestinal L-cells with a red fluorescent protein (RFP) 
was achieved by crossing GLU-Cre with ROSA26tdRFP 
reporter mice (Luche et al. 2007). To monitor calcium 
fluctuations in L-cells, these mice were crossed with commercially available ROSA26-GCaMP3 reporter mice 
(Zariwala et al. 2012) (Jax stock 014538) to generate 
L-cell specific expression of this genetically encoded Ca$^{2+}$ 
sensor. To monitor cAMP changes in L-cells, transgenic mice expressing Epac2camps under the control 
of the proglucagon promoter were used; the creation of 
these mice has been described previously (Psichas 
et al. 2016).

**Primary murine colonic crypt culture**

Colonic crypts were isolated and cultured as 
described previously (Reimann et al. 2008). Briefly, 
mice, aged 3–6 months, were killed by cervical dislocation 
and the colon was excised. Luminal contents were flushed 
throughly with phosphate-buffered saline and the 
outer muscle layer was removed. Tissue was minced and 
digested with collagenase type XI (0.4 mg ml$^{-1}$) and 
the cell suspension plated onto Matrigel (BD Bioscience, 
Oxford, UK) pre-coated 24-well plates for GLP-1 
secretion experiments or on 35 mm glass bottomed dishes 
(Mattek Corporation, Ashland, MA, USA) for calcium 
and cAMP imaging.

**Preparation of crypt cultures from human colons**

The present study was approved by the Research Ethics 
Committee under license number 09/H0308/24. Fresh 
surgical specimens of human colon were obtained from 
Tissue Bank at Addenbrooke’s Hospital (Cambridge, UK) 
stored at 4°C and processed within hours of surgery. 
The procedure was similar to that for mouse tissue, with 
the exception that the tissue was digested with a higher 
concentration of collagenase XI (0.5 mg ml$^{-1}$) (Habib 
et al. 2013).

**GLP-1 and PYY secretion assays**

Some 18–24 h after plating, cells were washed and 
icubated with test agents made up in standard bath 
solution supplemented with 0.1% BSA for 2 h at 37°C. 
At the end of the incubation, supernatants were collected 
and centrifuged at 400 g for 5 min and snap frozen 
on dry ice. Cells were lysed with lysis buffer containing 
(mm ol l$^{-1}$): 50 Tris-HCl, 150 NaCl, 1% IGEPAL-CA 630, 
0.5% deoxycholic acid and complete EDTA-free protease 
hinhibitor cocktail (Roche, Burgess Hill, UK) to extract 
intracellular peptides and centrifuged at 10,000 g for 
10 min and snap frozen. GLP-1 and PYY were measured 
using a total GLP-1 and total PYY assay (MesoScale 
Discovery, Gaithersburg, MD, USA) and supernatant 
concentrations were expressed as a percentage of the total 
(secreted + lysate) GLP-1 or PYY content of each well.

**Calcium imaging**

Intracellular calcium concentrations were monitored 
from colonic crypt cultures prepared from 
GlucCre/ROSA26-GCAMP3/ROSA26-tdRFP mice. 
L-cells were identified by RFP fluorescence and changes in 
intracellular calcium levels were represented by the change 
in the intensity of GCaMP3 fluorescence excited at 488 nm 
using a xenon arc lamp and a monochromator (Cairn
Research, Faversham, UK). Solutions were perfused continuously at a rate of ~1 ml min\(^{-1}\). Fluorescence in the presence of the test agent was normalized to the respective mean background fluorescence of each cell, measured before the addition and after the washout of the test compound. Data were smoothened with a sliding average across 20 s. Imaging was performed using an IX71 microscope (Olympus) with a 40× oil immersion objective and an OrcaER camera (Hamamatsu Photonics KK, Hamamatsu, Japan). Images were acquired at 1 Hz and analysed, after background subtraction, using MetaFluor software (Molecular Devices, Sunnyvale, CA, USA).

cAMP Förster resonance energy transfer measurements

Single-cell measurements of cAMP levels were made using intestinal cultures from transgenic mice expressing the Förster resonance energy transfer-based sensor Epac2-camps (Nikolaev et al. 2004) under the control of the proglucagon promoter. Briefly, primary colonic L-cells, continuously perfused with saline solution with or without test reagents at a rate of ~1 ml min\(^{-1}\), were visualized with a 40× oil immersion objective on an inverted microscope (Olympus IX71). Excitation at 435 nm was achieved using a xenon arc lamp coupled to a monochromator (Cairn Research) controlled by MetaFluor software (Molecular Devices). Cyan fluorescent protein (CFP) emission at 470 nm and yellow fluorescent protein (YFP) emission at 535 nm were monitored using an Optosplit II beam splitter (Cairn Research) and an Orca-ER digital camera (Hamamatsu Photonics KK) and expressed as the CFP/YFP fluorescence ratio. Data were smoothened with a sliding average across 30 s. Peak CFP/YFP ratios were determined at baseline (30 s period prior to test condition) and after test reagent application, and the response to test agent was expressed relative to baseline.

Quantitative RT-PCR

Populations of Venus-positive cells (L-cells) or Venus-negative cells (non-L-cells) of purity >90% were separated from the tissues of GLU-Venus mice using a MoFlo cell sorter (Beckman Coulter, High Wycombe, UK) as described previously (Reimann et al. 2008). RNA was extracted from FACS-sorted cells using a microscale RNA isolation kit (Ambion, Austin, TX, USA) and was then reverse transcribed to cDNA in accordance with standard protocols. The appropriate amount of first-strand cDNA template was mixed with specific TaqMan primers (Applied Biosystems, Foster City, CA, USA), water and PCR Master Mix (Applied Biosystems), and a quantitative RT-PCR was conducted using a 7900HT Fast Real-Time PCR system (Applied Biosystems). β-actin was used as the normalization control. The primer/probe pairs used in the present study were: Avpr1a: Mm00444092_m1; Avpr1b: Mm01700416_m1; and Avpr2: Mm01195354_g1 (all from Applied Biosystems). All experiments were performed on at least three cDNAs each isolated from one mouse (n = 3 mice).

Short circuit current (I\(_{sc}\)) measurement

The most distal part of the colon (~1.25 cm) was cut open longitudinally, rinsed in Ringer solution and mounted in an Ussing chamber (EM-LVSYS-4 system with P2400 chambers and P2404 sliders; Physiologic Instruments, San Diego, CA, USA). Only one preparation was used from each animal. The active epithelial surface was 0.25 cm\(^2\). Both parts of the Ussing chambers were filled with 3 ml of Ringer solution, maintained at 37°C and continuously bubbled with 5% v/v CO\(_2\)/95% v/v O\(_2\). The transepithelial potential difference was clamped to 0 mV using a DVC 1000 amplifier (WPI, Sarasota, FL, USA) and the resulting short circuit current was recorded via Ag-AgCl electrodes and 3 mol l\(^{-1}\) KCl agarose bridges. The recordings were collected and stored using a Digidata 1440A acquisition system and AxoScope, version 10.4 (Molecular Devices). The transepithelial resistance and short circuit current (I\(_{sc}\)) were allowed to stabilize for at least 30 min before the application of drugs. During this period, transepithelial resistance was assessed by measuring current changes in response to 2 mV pulses lasting 2.5 s, applied every 100 s. After stabilization of the electrical parameters, the drugs applied were: 5 μmol l\(^{-1}\) amiloride, 1 μmol l\(^{-1}\) BIBP3226 (BIBP) and 1 μmol l\(^{-1}\) AVP. A mix of forskolin (10 μmol l\(^{-1}\) + IBMX (100 μmol l\(^{-1}\) was applied bilaterally at the end of each experiment to confirm the responsiveness/viability of the tissue.

Human study design

Ethical approval was obtained to measure gut hormone concentrations in human serum samples that were left over after diagnostic testing was completed (REC 14/EE/1247; 1/12/2014). We selected blood samples from patients in which osmolality assessment had been requested for clinical reasons. Serum was collected using a separator tube, centrifuged within 4 h and stored at 4°C prior to analysis. Osmolality was measured using the freeze-point depression method (Model 3320 Osmometer; Advanced Instruments Inc., Norwood, Massachusetts, USA). Total PYY was measured using a commercially available sandwich immunoassay kit (MesoScale Discovery), which measures both the 1–36 and 3–36 forms of PYY.
The analytical range is 28–3000 pg ml\(^{-1}\). Inter-assay coefficients of variation of 7.8–16.4% were obtained within the physiological range. GLP-1 was not measured because it is not stable during prolonged storage at 4°C. To estimate the concentration of AVP, we measured copeptin, which is a cleavage product of pro-AVP released from the pituitary gland in equimolar quantities to AVP but has much greater stability in plasma and is easier to measure (Morgenthaler et al. 2006; Morgenthaler, 2010). Copeptin was measured using a sandwich immunoassay (USCN, Houston, TX, USA), which has an analytical range of 15.6–1000 pg ml\(^{-1}\).

We divided the samples into low/high osmolality (osmo) (\(<\) 295 mosmol kg\(^{-1}\); the upper limit of normal value) and low/high copeptin (\(<\) 300 pg ml\(^{-1}\); sensu Tenderenda-Banasiuk et al. 2014; Masajtis-Zagajewska et al. 2015). The clinical characteristics of the low osmo, high osmo, low copeptin and high copeptin groups, respectively, were: age (median) 77, 50, 69 and 59 years; body mass index (BMI) (median) 21.71, 28.25, 24.02 and 27.11 kg m\(^{-2}\); and sex (male/female) 18/14, 20/8, 21/8 and 14/12. Age was significantly higher and BMI significantly lower in the low osmo group compared to the high osmo group. No significant differences in age, BMI or sex were observed between the low and high copeptin groups.

**Statistical analysis**

The results are expressed as the mean ± SD unless otherwise indicated. Statistical analysis was performed using Prism, version 5.01 (GraphPad, San Diego, CA, USA). GLP-1 and PYY secretion data were analysed by two-way ANOVA, using experimental run and treatment type as variables. Secretion data were heteroscedastic and therefore log transformed. Post hoc testing was performed with post hoc Dunnett’s or Bonferroni tests as indicated. Statistical significance for Ca\(^{2+}\) imaging data was assessed by Student’s \(t\) test. Human serum samples that had PYY concentrations below the limit of detection were assigned a value of 28 pg ml\(^{-1}\) and the serum PYY levels were analysed non-parametrically by the Mann–Whitney test. \(P < 0.05\) was considered statistically significant.

**Results**

**Avpr1b expression is enriched in colonic L-cell population**

The expression of AVP receptors, Avpr1a (Fig. 1A), Avpr1b (Fig. 1B) and Avpr2 (Fig. 1C) was assessed by quantitative RT-PCR in L- and non-L-cell populations obtained by FACS sorting of epithelial cell suspensions from the upper and lower half of the mouse small intestine and large intestine. Of the three AVP receptors examined, Avpr1b was found to be highly enriched in both small intestinal and colonic L-cells compared to control cells and was much higher in colonic L-cell vs. small intestinal L-cell populations (Fig. 1B).

**AVP stimulates GLP-1 and PYY secretion from mouse colonic cultures**

To monitor GLP-1 and PYY secretion, primary crypt cultures were prepared from murine colonic tissue. Cells were stimulated for 2 h with different concentrations of AVP (10\(^{-13}\) to 10\(^{-6}\) mol l\(^{-1}\)) or with a positive control that was a combination of forskolin (10 \(\mu\)mol l\(^{-1}\)), IBMX (10 \(\mu\)mol l\(^{-1}\)) and glucose (10 mmol l\(^{-1}\)). AVP at or above 0.1 nmol l\(^{-1}\) caused a significant stimulation of GLP-1 secretion, which increased from 3.5% to comprise 28% of the total GLP-1 content with the highest concentration used (Fig. 2A). PYY secretion from murine colonic cultures was also assessed in response to 2 h of incubation with AVP (10 nmol l\(^{-1}\)) and increased from 9% to comprise 35% of the total PYY content (Fig. 2B).

**AVP elevates intracellular calcium concentrations in colonic L-cells**

To investigate the molecular mechanisms activated by exposure of L-cells to AVP, calcium fluctuations were monitored in primary L-cells cultured from the colon of GLU-Cre/ROSA26-GCaMP3 mice. These mice express the GCaMP3 protein, a genetically encoded Ca\(^{2+}\) sensor, specifically in L-cells and hence allow intracellular calcium levels to be monitored by exciting the GFP moiety of GCaMP3. AVP at a concentration of 10 nmol l\(^{-1}\) caused reversible and reproducible elevations of GCaMP3 fluorescence, which is indicative of an increase in intracellular calcium in colonic L-cells (Fig. 3A and B).

Intracellular calcium increase can either be caused by release of calcium from intracellular stores or influx of extracellular calcium via the opening of voltage-gated calcium channels in the plasma membrane. To distinguish these possibilities, calcium imaging experiments were performed in the presence of cobalt chloride (CoCl\(_2\)), a general voltage-gated calcium channel blocker that impairs L-cell calcium responses to depolarizing stimuli such as KCl (Pais et al. 2016b). Cytoplasmic calcium responses to AVP were still observed in the presence of CoCl\(_2\) (5 mmol l\(^{-1}\)) (Fig. 3C and D), suggesting a lack of dependence on voltage-gated calcium channels, which is consistent with the known Gq coupled nature of the AVPR1B.

**AVP elevates intracellular cAMP concentrations in colonic L-cells**

AVPR1B has been reported to activate both Gq-inositol phosphate and Gs-cAMP pathways, depending on...
the ligand and the localization within specialized compartments on the plasma membrane (Orcel et al. 2009). We tested the effect of AVP on intracellular cAMP levels in single L-cells in primary cultures prepared from transgenic mice expressing the Förster resonance energy transfer-based sensor Epac2-camps under the control of the proglucagon promoter. In colonic cultures, AVP (10 nmol l$^{-1}$) treatment resulted in an acute increase in the CFP/YFP fluorescence ratio, which is indicative of an elevation of cytosolic cAMP in L-cells (Fig. 4).

**Antagonist of AVPR1B reduces AVP-stimulated GLP-1 and PYY secretion**

To test the functional importance of AVPR1B, we performed GLP-1 and PYY secretion experiments in the presence of SSR (i.e. a selective vasopressin receptor antagonist with specificity for the AVPR1B subtype) (Serradeil-Le Gal et al. 2002; Serradeil-Le Gal et al. 2005). In mouse colonic cultures, SSR (1 μmol l$^{-1}$) significantly reduced AVP triggered GLP-1 and PYY release by ~70% and ~80%, respectively (Fig. 5). SSR on its own, however, had no effect on GLP-1 secretion (Fig. 5A).

**Figure 1. AVP receptors gene expression in L- and non-L-cell populations**

Avpr1a (A), Avpr1b (B) and Avpr2 (C) expression was analysed by quantitative RT-PCR from FACS-isolated L- (black) and non-L- (white) cells from the upper and lower small intestine (SI) and large intestine (LI) of mice and compared with that of Actb in the same sample. A Ct value of 40 was assigned to samples where the target gene was undetected. Data are presented as the geometric mean + upper SD of the 2$^{-\Delta\Delta Ct}$ data ($n=3$ each). Comparisons between L- and non-L-cells were assessed on non-transformed $\Delta\Delta Ct$ data using one-way ANOVA and post hoc Bonferroni analysis. ***$P<0.001$.

**Figure 2. AVP induced GLP-1 and PYY secretion from murine colonic cultures**

A, mixed intestinal cultures generated from mouse colons were incubated for 2 h in saline solution alone (Control; Con) or containing increasing concentrations of AVP or F/I/G, forskolin (10 μmol l$^{-1}$) plus IBMX (10 μmol l$^{-1}$) plus glucose (10 mmol l$^{-1}$). B, PYY secretion was measured from mixed cultures incubated with a single concentration of AVP (10 nmol l$^{-1}$). GLP-1 and PYY secretion is expressed as a percentage of total content. Results are shown as the mean + SD of (A) $n=9$ and (B) $n=13$ or 14 wells with 3 or 4 wells originating from a single mouse. ***$P<0.001$ compared to controls using one-way ANOVA followed by post hoc Bonferroni analysis on log$_{10}$ transformed data.
AVP stimulates GLP-1 and PYY secretion from human colonic cultures

To determine whether AVP has an effect on gut hormone secretion in humans, we used crypt cultures prepared from fresh human colon specimens obtained within a few hours of surgery. GLP-1 and PYY concentrations were measured in supernatants and cell lysates after 2 h of incubation in the presence of 10 nmol l\(^{-1}\) AVP. AVP significantly stimulated GLP-1 and PYY secretion by ~2-fold and 1.5-fold, respectively (Fig. 6). As in the murine cultures, SSR (1 \(\mu\)mol l\(^{-1}\)) significantly blocked the effect of AVP on GLP-1 release, suggesting that stimulation is mediated via AVPR1B in humans (Fig. 6A). The reduction of PYY release by SSR did not reach statistical significance in human cultures (Fig. 6B).

Anti-secretory effect of AVP in the mouse colon

We employed Ussing chambers to study the functional relevance of AVP in the mouse colon. Basolateral addition of AVP (1 \(\mu\)mol l\(^{-1}\)) caused a reduction in the short circuit current (\(I_\text{sc}\)) without any obvious change in the trans-epithelial resistance. In five of nine tissue preparations, the \(I_\text{sc}\) change followed a simple curve, reaching a plateau several minutes after the addition of AVP (Fig. 7Aa). The other samples showed more complicated kinetics, with an initial drop in \(I_\text{sc}\) and then a period of stabilization or even a slight increase in \(I_\text{sc}\), followed by a second fall (Fig. 7Ab). In all cases, \(I_\text{sc}\) remained depressed for at least 20 min after AVP addition. Pre-treatment with apically added amiloride (5 \(\mu\)mol l\(^{-1}\)) caused a decrease of \(I_\text{sc}\) that sometimes partially recovered, reaching a new plateau in

![Figure 3. Intracellular Ca\(^{2+}\) changes in colonic L-cells in response to AVP](image-url)

Mixed colonic cultures were generated from GLU-Cre/ROSA26-GCaMP3/ROSA26-tdRFP mice and L-cells were identified by their RFP fluorescence. A, representative trace showing calcium response to AVP (10 nmol l\(^{-1}\)) in an L-cell as a measure of GCaMP3 fluorescence. B, mean GCaMP3 fluorescence changes in L-cells in response to two applications of AVP in the same cell. \(n = 9\) cells and results are the mean \(\pm\) SD. **P < 0.001 compared to baseline by one-sample Student’s t test. C, representative trace showing calcium response to AVP (10 nmol l\(^{-1}\)) in the presence of cobalt chloride (CoCl\(_2\); 5 mmol l\(^{-1}\)) to block voltage-gated calcium channels and (D) mean calcium changes in L-cells in response to AVP (10 nmol l\(^{-1}\)) in the presence of CoCl\(_2\) (\(n = 6\) cells). Results are shown as the mean \(\pm\) SD. **P < 0.001 compared to baseline by a one-sample Student’s t test.
1–5 min. The mean $I_{sc}$ decrease as a result of amiloride was 4.37 $\mu$A cm$^{-2}$. Subsequent application of AVP, 10–12 min after amiloride, caused a further decrease in $I_{sc}$, which was no different from the decrease caused by AVP without any pretreatment (Fig. 7B and D). These findings suggest that the effect of AVP was a result of the decrease in electrogenic anion secretion and was not attributable to an interaction with ENaC-dependent sodium absorption. The results are in agreement with previously published results from Ussing chamber recordings (Bridges et al. 1984; Xue et al. 2014). Pre-treatment with the basolaterally added specific NPY1R antagonist BIBP caused an increase of $I_{sc}$, reaching a new plateau in 3–6 min. The mean $I_{sc}$ increase as a result of BIBP was 7.84 $\mu$A cm$^{-2}$. Subsequent application of AVP, 10–12 min after BIBP, triggered a significantly smaller drop in $I_{sc}$ compared to when AVP was applied without BIBP pretreatment, confirming a role of the PYY receptor NPY1R in AVP-mediated changes of colonic transepithelial ion movement (Fig. 7C and D).

**Human plasma PYY levels**

To assess whether PYY release is influenced by AVP in humans, we measured PYY and copeptin concentrations in anonymized human serum samples that had been sent for clinical measurement of osmolality. Copeptin, similar to AVP, is produced by post-translational processing of pre-provasopressin, although it is more stable in stored serum samples and can be used as an indirect measure of AVP concentrations (Morgenthaler et al. 2006). We hypothesized that serum PYY concentrations would be elevated in conditions of elevated copeptin or osmolality. Figure 8A and B shows the scatter of PYY concentrations plotted against osmolality and copeptin. Because we do not predict a linear effect on PYY, we divided the samples...
into low/high osmolality (<295 mosmol kg\(^{-1}\); the upper limit of normal value) and low/high copeptin (<300 pg ml\(^{-1}\); sensu Tenderenda-Banasiuk et al. 2014; Masajtis-Zagajewska et al. 2015). PYY was significantly higher in both the high osmolality and high copeptin groups (Fig. 8C and D).

Figure 6. GLP-1 and PYY secretion from human colonic cultures
Mixed intestinal cultures were generated from fresh human colonic tissues and stimulated with AVP (10 nmol l\(^{-1}\)) with or without the AVPR1B antagonist SSR (1 \(\mu\)mol l\(^{-1}\)). As in Fig. 5, wells that were co-incubated with AVP + SSR received a 30 min pre-treatment with the inhibitor. GLP-1 (A) and PYY (B) secretion is expressed as a percentage of total content. Results are shown as the mean + SD of (A) \(n=10–20\) wells and (B) \(n=8–18\) wells with 3 or 4 wells originating from a single tissue sample. **P < 0.01 and ***P < 0.001 compared to controls or as indicated using one-way ANOVA followed by post hoc Dunnett’s test or Bonferroni analysis on log\(_{10}\) transformed data.

Figure 7. AVP-induced effect on short circuit current in the mouse distal colon
A, traces showing changes in short circuit current recordings (\(I_{sc}\)) from mouse distal colon mounted in Ussing chambers after basolateral application of AVP (1 \(\mu\)mol l\(^{-1}\)). Both simple (a) and more complicated kinetics (b) are depicted. B, \(I_{sc}\) changes from colon tissue as in (A) but with the additional presence of apical amiloride (5 \(\mu\)mol l\(^{-1}\)) to block ENaC-dependent sodium absorption. C, \(I_{sc}\) changes from colon tissue as in (A) but with the additional presence of basolateral NPY1R antagonist BIBP (1 \(\mu\)mol l\(^{-1}\)). D, mean changes in Isc after application of AVP alone or in the presence of BIBP or amiloride (Amil.). \(\Delta I_{sc}\) was calculated as the difference between the means of short circuit currents from the 2–5 min period before and 15 min period after the application of AVP. Data are the mean ± SD from five to nine tissue preparations, normalized for a surface area of 1 cm\(^2\). ***P < 0.001 compared to AVP application alone using one-way ANOVA followed by post hoc Bonferroni analysis on non-transformed data.
Discussion

In the present study, we have shown, for the first time, that AVP stimulates GLP-1 and PYY secretion from colonic L-cells isolated from mice and humans. It acts via the Gq/Gs coupled receptor AVPR1B, which was found to be highly expressed in colon and was particularly enriched in L-cells over the neighbouring epithelial cells. In support of this idea, a selective antagonist of AVPR1B significantly decreased AVP-stimulated hormone release in both mouse and human colonic cultures. Because the action of AVP was not completely abolished by the antagonist, however, we cannot exclude the possibility that the alternative receptors, AVPR1A and AVPR2, also play a role. In vitro, AVP-stimulation of L-cells raised both intracellular cAMP and calcium and triggered the secretion of both PYY and GLP-1. One of the known actions of PYY is mediated via Y1 receptors located on neighbouring enterocytes, reducing anion and water secretion to the colonic lumen and ultimately altering local intestinal water balance in the direction of water conservation. This proposed mechanism provides an explanation for some of the previously observed local in vitro effects of AVP in the colon, notably a decrease in short circuit current, a decrease in chloride secretion, and an increase in net water and anion absorption (Bridges et al. 1983; Bridges et al. 1984; Vicentini-Paulino, 1992; Xue et al. 2014). Given the amount of water secreted into the gastrointestinal tract, which is estimated to be ~8 litres/24 h in humans (Barrett & Keely, 2000), it is possible that the modulation of intestinal secretion through this pathway could have an impact on the systemic circulation. Indeed, I.V. infusion of high doses of PYY to healthy volunteers increased both diastolic and systolic blood pressure (Adrian et al.)

Figure 8. Plasma PYY measurements in human serum samples

A, scatter plot showing total PYY (pg ml⁻¹) plotted against osmolality (mosmol kg⁻¹) in human serum samples. Samples were divided into low osmo and high osmo groups with a cut-off limit set at 295 mosmol kg⁻¹ (vertical dashed line). B, total PYY (pg ml⁻¹) was plotted for the two groups: low osmo (circles) and high osmo (squares). C, scatter plot showing total PYY (pg ml⁻¹) plotted against copeptin (pg ml⁻¹) in human serum samples. Copeptin (cpp) was measured as a surrogate marker for AVP in the serum. Samples were divided into a low and high group with a cut-off set at 300 pg ml⁻¹ (vertical dashed line) and (D) total PYY (pg ml⁻¹) was plotted for the two groups: low cpp (circles) and high cpp (squares). Statistical comparison was made for PYY in the high and low groups by the Mann–Whitney test. *P < 0.05 and **P < 0.01 for low and high groups.

© 2016 The Authors The Journal of Physiology published by John Wiley & Sons Ltd on behalf of The Physiological Society
AVP stimulates GLP-1 and PYY secretion from mouse and human colons

Our data additionally suggest that serum osmolality and AVP levels influence circulating PYY concentrations in humans, raising the possibility of more systemic consequences of AVP-triggered secretion from intestinal L-cells. Age and BMI were significantly different in the low vs. high osmolality but not between the copeptin groups, with the low osmo group having both a lower BMI and lower PYY than the high osmo group. Because previous studies reported that PYY levels are inversely related to BMI (Batterham et al. 2003), the BMI difference probably does not account for the difference in PYY observed in the present study. Also, there was no influence of age on PYY in healthy population (MacIntosh et al. 1999). More experiments will be needed to determine whether the described modulation of L-cells by AVP is involved in the control of physiological hormonal blood volume/pressure and glucose homeostasis or is solely aimed at the local regulation of intestinal water and ionic movements.

Although it is relatively straightforward to appreciate a possible role of AVP-induced PYY release, we can only speculate about the purpose of the simultaneous GLP-1 secretion. A single study has reported anionic secretory responses of murine intestinal epithelium to endogenously released GLP-1, as well as to application of the GLP1R agonist exendin-4 (Joshi et al. 2013). Other studies, however, did not report any response to GLP-1 in guinea-pig ileum, even at high concentrations (Baldassano et al. 2012). Similarly, we did not observe any changes in basal short circuit current in response to either GLP-1 or exendin-4 stimulation in preparations from the murine distal colon mounted in Ussing chambers (data not shown). This obviously does not preclude the possibility that GLP-1 might affect other parts of the intestine or do so under different experimental conditions. In another study, GLP-1 was shown to suppress epithelial secretory responses to electrical stimulation of submucosal neurons (Baldassano et al. 2012). This raises the interesting hypothesis that co-released PYY and GLP-1 possess complementary properties with respect to intestinal salt and water balance, inhibiting basal (PYY) as well as neurally stimulated (GLP-1) anion secretion. Indeed, AVP itself was also shown to inhibit neurally stimulated secretory responses (Knobloch et al. 1989). However, we did not observe any exendin-4 related inhibition of secretory responses to electrical field stimulation in our preparations from the mouse distal colon (data not shown). There is also an intriguing possibility that AVP-induced GLP-1 secretion increases intestinal water uptake via its stimulatory effect on the hypothalamic-pituitary-adrenal axis. Indeed, peripheral administration of GLP-1 or exendin-4 increased levels of both corticosterone and aldosterone in rats, whereas bolus I.V. GLP-1 increased systemic levels of cortisol in humans (Gil-Lozano et al. 2010; Gil-Lozano et al. 2014). Prolonged administration of exendin-4 or other GLP-1 receptor agonists was also associated with increased corticosterone levels and increased water intake in rodents (Gil-Lozano et al. 2013; Krass et al. 2015). Glucocorticoids are known to increase intestinal sodium and water absorption from small and large intestine as a result of their effect on Na⁺/K⁺ ATPase, NHE3 and SGLT1 activity. Under this mechanism, the effects of AVP-stimulated GLP-1 and PYY secretion would also be complementary, with PYY reducing anion and water secretion via its direct short term effect on enterocytes, whereas GLP-1 increases sodium and water absorption via its longer-term modulation of glucocorticoid levels. Of note, ablation of AVP1B activity by antagonists or by use of knockout animals leads to decreased levels of glucocorticoids in the circulation, although, here, a central direct action of AVP independent of GLP-1 has been postulated (Koshimizu et al. 2012).

Other than its role in water retention and blood pressure control, AVP is increasingly recognized as an active player in the regulation of glucose homeostasis. AVP1B-mediated GLP-1 release from intestinal L-cells could provide an additional level of complexity to the direct stimulatory effect of AVP on pancreatic insulin and glucagon secretion (Lee et al. 1995; Yibchok-Anun et al. 2000; Abu-Basha et al. 2002). For example, the elevated AVP levels observed in uncontrolled diabetes (Vokes et al. 1987) might not only maintain fluid balance, but also stimulate insulin secretion by promoting GLP-1 release, thereby counteracting the hyperglycaemic state.

In summary, the data obtained in the present study show, for the first time, the role of L-cells in AVP regulated intestinal fluid secretion, potentially linking the hormonal control of blood volume and blood glucose levels. Although therapies based on GLP-1 physiology have been highly successful in the treatment of type 2 diabetes, the alteration of intestinal salt and water balance has recently been recognized as a promising target for novel drugs against hypertension, heart failure, end-stage renal disease and chronic kidney disease (Spencer et al. 2014). Thus, clarifying the exact role of L-cells in the cross-talk between blood volume/pressure and blood glucose control could be of potential interest with respect to our understanding of the range of diseases currently posing a significant burden on modern society.

References

Abu-Basha EA, Yibchok-Anun S & Hsu WH (2002). Glucose dependency of arginine vasopressin-induced insulin and glucagon release from the perfused rat pancreas. Metabolism 51, 1184–1190.

Adrian TE, Sagor GR, Savage AP, Bacarese-Hamilton AJ, Hall GM & Bloom SR (1986). Peptide YY kinetics and effects on blood pressure and circulating pancreatic and gastrointestinal hormones and metabolites in man. J Clin Endocrinol Metab 63, 803–807.
Baldassano S, Wang GD, Mulè F & Wood JD (2012). Glucagon-like peptide-1 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro. *Am J Physiol Gastrointest Liver Physiol* 302, G352–G358.

Barrett KE & Keely SJ (2000). Chloride secretion by the intestinal epithelium: molecular basis and regulatory aspects. *Ann Rev Physiol* 62, 535–572.

Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatéi MA & Bloom SR (2003). Inhibition of food intake in obese subjects by peptide YY3-36. *N Engl J Med* 349, 941–948.

Binder HJ, McGlone F & Sandle GI (1989). Effects of corticosteroid hormones on the electrophysiology of rat distal colon: implications for Na⁺ and K⁺ transport. *J Physiol* 410, 425–441.

Bridges RJ, Nell G & Rummel W (1983). Influence of vasopressin and calcium on electrolyte transport across isolated colonic mucosa of the rat. *J Physiol* 338, 463–475.

Bridges RJ, Rummel W & Wollenberg P (1984). Effects of vasopressin on electrolyte transport across isolated colon from normal and dexamethasone-treated rats. *J Physiol* 355, 11–23.

Charney AN, Kinsey MD, Myers L, Gainella RA & Gots RE (1979). Intestinal electrolyte transport. Effect of adrenal steroids. *J Clin Invest* 56, 653–660.

Cox HM (2007a). Neuropeptide Y receptors; antisecretory control of intestinal epithelial function. *Auton Neurosci* 133, 76–85.

Cox HM (2007b). Peptide YY: a neuroendocrine neighbor of note. *Peptides* 28, 345–351.

Cox HM (2008). Endogenous PYY and NPY mediate tonic Y1- and Y2-mediated absorption in human and mouse colon. *Nutrition* 24, 900–906.

Cristià E, Amat C, Naftalin RJ & Moret E (2013). GLP-1(7-36)-amide and exendin-4 stimulate the hypothalamic-pituitary-adrenal axis of male rats. *Endocrinology* 155, 2511–2523.

Grady GF, Duhamel RC & Moore EW (1970). Active transport of sodium by human colon in vitro. *Gastroenterology* 59, 583–588.

Gribble FM & Reimann F (2015). Enteroendocrine cells: chemosensors in the intestinal epithelium. *Ann Rev Physiol* 78, 277–299.

Habib AM, Richards P, Rogers GJ, Reimann F & Gribble FM (2013). Co-localisation and secretion of glucagon-like peptide 1 and peptide YY from primary cultured human L cells. *Diabetologia* 56, 1413–1416.

Joshi S, Tough IR & Cox HM (2013). Endogenous PYY and GLP-1 mediate l-glutamine responses in intestinal mucosa. *Br J Pharmacol* 170, 1092–1101.

Knobloch SF, Diener M & Rummel W (1989). Antisecretory effects of somatostatin and vasopressin in the rat colon descendens in vitro. *Regul Pept* 25, 75–85.

Koshimizu TA, Nakamuraka K, Egashira N, Hiroyama M, Nonoguchi H & Tanoue A (2012). Vasopressin V1a and V1b receptors: from molecules to physiological systems. *Physiol Rev* 92, 1813–1864.

Krass M, Volke A, Rünkorg K, Wegener G, Lund S, Abildgaard A, Vasar E & Volke V (2015). GLP-1 receptor agonists have a sustained stimulatory effect on corticosterone release after chronic treatment. *Acta Neuropsyciatr* 27, 25–32.

Launay JM, Vittet D, Vidaud M, Rondot A, Mathieu MN, Lalau-Keraly C, Cantau B & Chevillard C (1987). V1a-vasopressin specific receptors on human platelets: potentiation by ADP and epinephrine and evidence for homologous down-regulation. *Thromb Res* 45, 323–331.

Lee B, Yang C, Chen TH, al-Azawi N & Hsu WH (1995). Effect of AVP and oxytocin on insulin release: involvement of V1b receptors. *Am J Physiol Endocrinol Metab* 269, E1095–E1100.

Levitan R & Ingelfinger FJ (1965). Effect of D-Aldosterone on salt and water absorption from the intact human colon. *J Clin Invest* 44, 801–808.

Levitan R & Mauer I (1968). Effect of intravenous antiadrenergic hormone administration on salt and water absorption from the human colon. *J Lab Clin Med* 72, 739–746.

Luche H, Weber O, Nageswara Rao T, Blum C & Fehling HJ (2007). Faithful activation of an extra-bright red fluorescent protein in ‘knock-in’ Cre-reporter mice ideally suited for lineage tracing studies. *Eur J Immunol* 37, 43–53.

MacIntosh CG, Andrews JM, Jones KL, Wishart JM, Morris HA, Jansen JB, Morley JE, Horowitz M & Chapman IM (1999). Effects of age on concentrations of plasma cholecystokinin, glucagon-like peptide 1, and peptide YY and their relation to appetite and pyloric motility. *Am J Clin Nutr* 69, 999–1006.

Masajtis-Zagajewska A, Kurnatowska I, Wajdlich M & Nowicki M (2015). Utility of copeptin and standard inflammatory markers in the diagnostics of upper and lower urinary tract infections. *BMC Urol* 15, 67.
Monstein HJ, Truedsson M, Ryberg A & Ohlsson B (2008). Vasopressin receptor mRNA expression in the human gastrointestinal tract. *Eur Surg Res* **40**, 34–40.

Morgenthaler NG (2010). Copeptin: a biomarker of cardiovascular and renal function. *Congest Heart Fail* **16** Suppl 1, S37–S44.

Morgenthaler NG, Struck J, Alonso C & Bergmann A (2006). Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. *Clin Chem* **52**, 112–119.

Nikolaev VO, Bünemann M, Hein L, Hannawacker A & Lohse MJ (2004). Novel single chain CAMP sensors for receptor-induced signal propagation. *J Biol Chem* **279**, 37215–37218.

Orcel H, Albizu L, Perkovska S, Durrous T, Mendre C, Ansany H, Mouilac B & Rabié A (2009). Differential coupling of the vasopressin V1b receptor through compartmentalization within the plasma membrane. *Mol Pharmacol* **75**, 637–647.

Pais R, Gribble FM & Reimann F (2016a). Stimulation of incretin secreting cells. *Ther Adv Endocrinol Metab* **7**, 24–42.

Pais R, Gribble FM & Reimann F (2016b). Signalling pathways involved in the detection of peptides by murine small intestinal enteroendocrine L-cells. *Peptides** **77**, 9–15.

Parker HE, Adriaenssens A, Rogers G, Richards P, Koepsell H, Reimann F & Gribble FM (2012). Predominant role of active versus facilitative glucose transport for glucagon-like peptide-1 secretion. *Diabetologia* **55**, 2445–2455.

Playford RJ, Domin J, Beacham J, Parmar KB, Tatemoto K, Bloom SR & Calam J (2000). Preliminary report: role of peptide YY in defence against diarrhoea. *Lancet* **355**, 1555–1557.

Pschas A, Glass LL, Sharp SJ, Reimann F & Gribble FM (2016). Galanin inhibits GLP-1 and GIP secretion via the GAL1 receptor in enteroendocrine L and K cells. *Br J Pharmacol* **173**, 888–898.

Pyke C, Heller RS, Kirk RK, Örskov C, Reedtz-Runge S, Kaastrup P, Hvelplund A, Bardram L, Calatayud D & Knudsen LB (2014). GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with an extensively validated monoclonal antibody. *Endocrinology* **155**, 1280–1290.

Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ & Gribble FM (2008). Glucose sensing in L cells: a primary cell study. *Cell Metabolism* **8**, 532–539.

Richards P, Parker HE, Adriaenssens AE, Hodgson JM, Cork SC, Trapp S, Gribble FM & Reimann F (2014). Identification and characterization of GLP-1 receptor-expressing cells using a new transgenic mouse model. *Diabetes* **63**, 1224–1233.

Serradell-Le Gal C, Wagon J, Simiand J, Griebel G, Lacour C, Guillou G, Barberis C, Brossard G, Soubrié P, Nisato D, Pascal M, Pruss R, Scallon B, Maffrand JP & Le Fur G (2002). Characterization of (25R)-1-[5-chloro-1-(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a selective and orally active vasopressin V1b receptor antagonist. *J Pharmacol Exp Ther* **300**, 1122–1130.
the data for the work and revised the manuscript critically for intellectual content. FMG and FR conceived and designed the work; analysed and interpreted the data; and drafted and revised the manuscript critically for important intellectual content. We confirm that the final version of the manuscript has been read and approved by all named authors and we take responsibility for all aspects of the work to ensure that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Furthermore, all persons designated as authors qualify for authorship, and all those who qualify for authorship are listed.

**Funding**

This work was funded by grants from the Wellcome Trust (106262/Z/14/Z, 106263/Z/14/Z), the MRC Metabolic Diseases Unit (MRC_MC_UU_12012/3) and Full4Health (FP7/2011-2015, grant agreement no 266408). Juraj Rievaj was initially supported by an EFSD Albert Renold Travel Fellowship.

**Acknowledgements**

GLP-1 and PYY immunoassays (MesoScale Discovery) were performed by Keith Burling, Peter Barker and colleagues at the Core Biochemical Assay Laboratory. Cell sorting was conducted by Reiner Schulter and colleagues at the Cambridge Institute for Medical Research. The Human Research Tissue Bank is supported by the NIHR Cambridge Biomedical Research Centre. Hannah B. Lewis provided helpful advice on making applications to regulatory bodies.